First-in-human phase I study of a selective c-Met inhibitor volitinib (HMP504/AZD6094) in patients with advanced solid tumors

Category Primary study
JournalJournal of Clinical Oncology
Year 2014
This article has no abstract
Epistemonikos ID: caab7ad7b2752e52f596dcf5e7d316a7c4a5323a
First added on: Feb 06, 2025